Compare prices and buy Aviptadil from 1 research peptide vendor - also called suppliers or sources. Updated daily.
The international nonproprietary name for synthetic vasoactive intestinal peptide (CAS 40077-57-4), identical to native VIP across all 28 residues (HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2, C147H238N44O42S, amidated C-terminus). It acts on the VPAC1 and VPAC2 receptors. It has been developed as an erectile dysfunction injection in combination with phentolamine and as an intravenous treatment for COVID-19 respiratory failure, and it is not FDA-approved for any indication.
For research purposes only. Not medical advice.
Listed prices for in-stock single vials, before coupon codes. Kits are left out.
Aviptadil is the international nonproprietary name for synthetic vasoactive intestinal peptide, the same 28-residue molecule as VIP. The VIP page covers its chemistry, receptors, half-life and compounding status, along with the published trials in pulmonary hypertension, sarcoidosis and COVID-19. This page covers the drug programs run under the aviptadil name and the regulatory decisions they produced.
The UK medicines regulator's product database lists one product under the substance aviptadil as of October 2026. It is Invicorp, a solution for injection that combines aviptadil with phentolamine mesilate and is listed under both substances. It is an intracavernosal injection, given into the penis, for erectile dysfunction.
A multicentre, double-blind, placebo-controlled study at eight institutions tested the combination in a prefilled auto-injector in men with predominantly nonpsychogenic erectile dysfunction (Dinsmore and colleagues, BJU International, 1999). Of the 171 men in its placebo-controlled phase, 75 and 66 percent responded at the two phentolamine strengths tested, against 12 and 18 percent on placebo. Transient facial flushing accompanied 40 percent of injections and was the main adverse event.
A 2025 retrospective review covered 308 men at a single center, all referred after alprostadil injections had caused intolerable pain or failed. It counted 59 percent as treated effectively, defined as resuming intercourse by the three-month check, and had no comparison group (Al-Mitwalli and colleagues, Journal of Sexual Medicine). Facial flushing was again the most common adverse event.
NeuroRx, now NRx Pharmaceuticals, developed intravenous aviptadil for COVID-19 respiratory failure in partnership with Relief Therapeutics, first under the code RLF-100 and later under the brand name Zyesami. The decisions it produced:
The results of the randomized intravenous trials, TESICO among them, and of the inhaled trial run at Turkish centers are on the VIP page.
No FDA-approved drug contains aviptadil. As of October 21, 2026:
The Indian recommendation covers restricted emergency use in that one indication, on conditions that include sale only on a medical specialist's prescription and a fact sheet for health care professionals.
Invicorp is a solution for injection that combines aviptadil, the synthetic form of vasoactive intestinal peptide, with phentolamine mesilate. The UK medicines regulator's product database lists it under both substances as of October 2026. It is an intracavernosal injection for erectile dysfunction, and a multicentre double-blind placebo-controlled study published in BJU International in 1999 tested the combination in a prefilled auto-injector. Invicorp has no FDA approval, and a research listing titled Aviptadil names the peptide alone, so it is not this combination product.
No. FDA granted Fast Track designation to the intravenous program, then called RLF-100, in June 2020, according to its developers NeuroRx and Relief Therapeutics. In November 2021 NRx Pharmaceuticals announced that FDA had declined its request for emergency use authorization of the product, by then branded Zyesami, citing insufficient data on its benefits and risks in critical COVID-19 with respiratory failure. NRx later announced that FDA had also declined Breakthrough Therapy designation and, in July 2022, a narrower emergency use request based on a post-hoc subgroup analysis. In May 2022 the safety board of the NIH's TESICO trial had recommended stopping its aviptadil comparison for futility.
Not in the United States. Elsewhere, in April 2022 a subject expert committee of India's Central Drugs Standard Control Organisation recommended permission for Zuventus Healthcare to manufacture and market an aviptadil injection for restricted use under emergency situations in severe COVID-19 with acute respiratory distress syndrome, on condition that it be sold only on a medical specialist's prescription. In July 2021 NRx Pharmaceuticals announced an emergency use authorization of its product, Zyesami, in the nation of Georgia.
Both are names for aviptadil in its COVID-19 program. RLF-100 is the code NeuroRx and Relief Therapeutics used when they announced FDA Fast Track designation in June 2020. Zyesami is the brand name NRx Pharmaceuticals, the company NeuroRx became, later used for its intravenous and inhaled aviptadil products. Neither has an FDA approval.
No. As of October 21, 2026, ClinicalTrials.gov lists no recruiting study of aviptadil. The one record still marked active, the I-SPY COVID adaptive platform trial for critically ill patients, lists its aviptadil arm as closed. The completed and terminated records include the NIH's TESICO trial, an intravenous Phase 2/3 trial in critical COVID-19 and inhaled trials in COVID-19.
Aviptadil is sold by 1 research peptide vendor indexed on PeptideScouter. The lowest listed in-stock prices are at Biotech Compounds ($21.60/mg). The table above compares all 1 tracked listing by vendor, refreshed daily.
All 1 indexed research peptide vendor currently have Aviptadil in stock. Stock state is refreshed daily from each vendor's catalog.
Biotech Compounds currently lists Aviptadil at $21.60/mg, the lowest listed price across 1 tracked research peptide vendor. With current vendor discount codes applied, the lowest effective price is $19.44/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 1 vendor listing Aviptadil publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $21.60/mg listed to $19.44/mg at Biotech Compounds. Each vendor's code is shown beside its price in the table above.
10 mg vials list from $215.99 (median $215.99 across 1 in-stock listing). Prices are refreshed daily.
Aviptadil's CAS Registry Number is 40077-57-4.